Showing 141 - 160 results of 425 for search '"liver transplantation"', query time: 0.09s Refine Results
  1. 141

    Achieving Complete Remission of Hepatocellular Carcinoma: A Significant Predictor for Recurrence-Free Survival after Liver Transplantation by Christin Bürger, Miriam Maschmeier, Anna Hüsing-Kabar, Christian Wilms, Michael Köhler, Martina Schmidt, Hartmut H. Schmidt, Iyad Kabar

    Published 2019-01-01
    “…Background. Liver transplantation (LT) is a curative treatment for hepatocellular carcinoma (HCC) and the underlying primary liver disease; however, tumor recurrence is still a major issue. …”
    Get full text
    Article
  2. 142

    Ligation of Left Renal Vein for Spontaneous Splenorenal Shunt to Prevent Portal Hypoperfusion after Orthotopic Liver Transplantation by Lampros Kousoulas, Kristina Imeen Ringe, Michael Winkler, Frank Lehner, Nicolas Richter, Juergen Klempnauer, Fabian Helfritz

    Published 2013-01-01
    “…We report a case of recovered portal flow by ligation of the left renal vein on the first postoperative day after orthotopic liver transplantation of a 54-year-old female with alcoholic liver cirrhosis, chronic kidney failure, and spontaneous splenorenal shunt. …”
    Get full text
    Article
  3. 143
  4. 144

    Validation of the Model of End-Stage Liver Disease for Liver Transplant Allocation in Alberta: Implications for Future Directions in Canada by Kelly W. Burak, Glenda A. Meeberg, Robert P. Myers, Gordon H. Fick, Mark G. Swain, Vincent G. Bain, Norman M. Kneteman, Robert J. Hilsden

    Published 2016-01-01
    “…Since 2002, the Model of End-Stage Liver Disease (MELD) has been used for allocation of liver transplants (LT) in the USA. In Canada, livers were allocated by the CanWAIT algorithm. …”
    Get full text
    Article
  5. 145

    Inherited metabolic diseases are a potent risk factor for cytomegalovirus infection in pediatric living donor liver transplantation by Kentaro Ushijima, Yukihiro Sanada, Shinya Otomo, Keiko Ogaki, Taiichi Wakiya, Noriki Okada, Yuta Hirata, Toshio Horiuchi, Takahiko Omameuda, Kiichiro Takadra, Ryosuke Akimoto, Yasuharu Onishi, Yasunaru Sakuma, Koichi Mizuta

    Published 2025-01-01
    “…Conclusions This study demonstrates that IMDs are a potent independent risk factor for CMV infection following pediatric liver transplantation. Clinical trial number Not applicable.…”
    Get full text
    Article
  6. 146
  7. 147
  8. 148

    Health-Related Quality of Life after Pediatric Liver Transplantation: A Qualitative Analysis of the Perspectives of Health Care Providers by Mar Miserachs, David B. Nicholas, Anthony R. Otley, Vicky Lee Ng

    Published 2017-01-01
    “…With improved survival outcomes after pediatric liver transplantation (LT), health-related quality of life (HRQoL) is an important outcome metric. …”
    Get full text
    Article
  9. 149

    Liver Transplantation without Perioperative Transfusions Single-Center Experience Showing Better Early Outcome and Shorter Hospital Stay by Nicolás Goldaracena, Patricio Méndez, Emilio Quiñonez, Gustavo Devetach, Lucio Koo, Carlos Jeanes, Margarita Anders, Federico Orozco, Pablo D. Comignani, Ricardo C. Mastai, Lucas McCormack

    Published 2013-01-01
    “…Significant amounts of red blood cells (RBCs) transfusions are associated with poor outcome after liver transplantation (LT). We report our series of LT without perioperative RBC (P-RBC) transfusions to evaluate its influence on early and long-term outcomes following LT. …”
    Get full text
    Article
  10. 150
  11. 151

    Safety and Tolerance of Donor-Derived Mesenchymal Stem Cells in Pediatric Living-Donor Liver Transplantation: The MYSTEP1 Study by Steffen Hartleif, Michael Schumm, Michaela Döring, Markus Mezger, Peter Lang, Marc H. Dahlke, Joachim Riethmüller, Alfred Königsrainer, Rupert Handgretinger, Silvio Nadalin, Ekkehard Sturm

    Published 2017-01-01
    “…Calcineurin inhibitors (CNI) have significantly improved patient and graft survival in pediatric liver transplantation (pLT). However, CNI toxicity leads to significant morbidity. …”
    Get full text
    Article
  12. 152
  13. 153
  14. 154
  15. 155
  16. 156
  17. 157
  18. 158
  19. 159

    Th1/Th2 cytokines and ICAM–1 levels post-liver transplant do not predict early rejection by E. Granot, A. Tarcsafalvi, S. Emre, P. Sheiner, S. Guy, M. E. Schwartz, P. Boros, C. M. Miller

    Published 2000-01-01
    “…Thus, Th1/Th2 cytokine monitoring during the first week post-transplant does not predict early rejection and immunosuppressive therapy is the predominant factor affecting ICAM and sIL–2R levels after liver transplantation.…”
    Get full text
    Article
  20. 160